ADC THERAPEUTICS SA's ticker is ADCT and the CUSIP is H0036K147. A total of 52 filers reported holding ADC THERAPEUTICS SA in Q4 2020. The put-call ratio across all filers is 5.38 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $5,934,174 | -1.6% | 2,760,081 | -10.7% | 0.00% | 0.0% |
| Q1 2023 | $6,029,000 | +52153.4% | 3,091,814 | +2.9% | 0.00% | -50.0% |
| Q4 2022 | $11,538 | -99.9% | 3,004,466 | -12.1% | 0.00% | 0.0% |
| Q3 2022 | $16,468,000 | -40.0% | 3,416,517 | -1.1% | 0.00% | -50.0% |
| Q2 2022 | $27,456,000 | -45.3% | 3,453,672 | +1.1% | 0.00% | -33.3% |
| Q1 2022 | $50,162,000 | -22.3% | 3,414,630 | +6.9% | 0.01% | -14.3% |
| Q4 2021 | $64,536,000 | -27.3% | 3,194,842 | -2.2% | 0.01% | -36.4% |
| Q3 2021 | $88,759,000 | +14.0% | 3,267,986 | +2.2% | 0.01% | +22.2% |
| Q2 2021 | $77,876,000 | +1.5% | 3,198,208 | +1.8% | 0.01% | -10.0% |
| Q1 2021 | $76,702,000 | -19.8% | 3,142,253 | +5.2% | 0.01% | -28.6% |
| Q4 2020 | $95,612,000 | +39.3% | 2,986,918 | +43.0% | 0.01% | +16.7% |
| Q3 2020 | $68,643,000 | +28.3% | 2,088,312 | +82.7% | 0.01% | +20.0% |
| Q2 2020 | $53,493,000 | – | 1,142,773 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Vantage Consulting Group Inc | 1,186,215 | $4,555,066 | 2.69% |
| Blue Owl Capital Holdings LP | 733,568 | $2,816,901 | 1.20% |
| Redmile Group, LLC | 7,590,849 | $29,148,860 | 1.19% |
| AlphaCentric Advisors LLC | 297,500 | $1,142,400 | 1.13% |
| Prosight Management, LP | 463,310 | $1,779,110 | 0.97% |
| GCM Grosvenor Holdings, LLC | 735,471 | $2,824,209 | 0.72% |
| Indie Asset Partners, LLC | 93,839 | $360,342 | 0.40% |
| XTX Topco Ltd | 197,635 | $758,918 | 0.16% |
| Eventide Asset Management | 1,879,959 | $7,219,043 | 0.14% |
| Nantahala Capital Management | 243,290 | $934,234 | 0.06% |